Open-Label Extension (OLE) Safety and Efficacy Study of Velneperit (S-2367) Following the Year-Long Controlled Clinical Trials of S-2367 in Obese Males and Females.

Trial Profile

Open-Label Extension (OLE) Safety and Efficacy Study of Velneperit (S-2367) Following the Year-Long Controlled Clinical Trials of S-2367 in Obese Males and Females.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2011

At a glance

  • Drugs Velneperit (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Sponsors Shionogi USA
  • Most Recent Events

    • 26 Mar 2010 Actual patient number (766) added as reported by ClinicalTrials.gov.
    • 26 Mar 2010 Actual end date (March 2010) added as reported by ClinicalTrials.gov.
    • 26 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top